TuHURA Biosciences IncNASDAQ:HURA
- LAST PRICE5.2700
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots4.7500/ 1
- Ask / Lots5.5000/ 1
- Open / Previous Close--- / 5.2700
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | HURA |
|---|---|---|
| 09:32 ET | 1998 | 5.39 |
| 09:33 ET | 120 | 5.03 |
| 09:37 ET | 322 | 5.02 |
| 09:46 ET | 1307 | 5.06 |
| 09:48 ET | 151 | 5.06 |
| 09:53 ET | 100 | 5.03 |
| 09:55 ET | 643 | 5.1013 |
| 10:00 ET | 239 | 5.19 |
| 10:02 ET | 100 | 5.19 |
| 10:06 ET | 2000 | 5.0379 |
| 10:22 ET | 100 | 5.32 |
| 10:24 ET | 100 | 5.36 |
| 10:31 ET | 100 | 5.35 |
| 10:42 ET | 100 | 5.35 |
| 10:44 ET | 718 | 5.3379 |
| 10:45 ET | 661 | 5.35 |
| 10:58 ET | 100 | 5.34 |
| 11:02 ET | 189 | 5.1201 |
| 11:07 ET | 100 | 5.34 |
| 11:12 ET | 100 | 5.34 |
| 11:20 ET | 100 | 5.3 |
| 11:27 ET | 1292 | 5.33 |
| 11:36 ET | 100 | 5.34 |
| 11:43 ET | 100 | 5.34 |
| 11:45 ET | 150 | 5.1752 |
| 12:06 ET | 100 | 5.39 |
| 12:19 ET | 100 | 5.4 |
| 12:35 ET | 500 | 5.3115 |
| 12:39 ET | 100 | 5.4 |
| 12:46 ET | 100 | 5.4 |
| 12:48 ET | 100 | 5.315 |
| 01:00 ET | 100 | 5.4 |
| 01:02 ET | 1173 | 5.2648 |
| 01:09 ET | 1300 | 5.26 |
| 01:20 ET | 100 | 5.375 |
| 01:40 ET | 300 | 5.21 |
| 01:56 ET | 1200 | 5.13 |
| 02:03 ET | 200 | 5.11 |
| 02:05 ET | 311 | 5.1 |
| 02:16 ET | 100 | 5.08 |
| 02:23 ET | 100 | 5.07 |
| 02:25 ET | 100 | 5.08 |
| 02:34 ET | 100 | 5.14 |
| 02:43 ET | 130 | 5.06 |
| 02:48 ET | 1397 | 5.05 |
| 02:56 ET | 100 | 5.14 |
| 02:57 ET | 300 | 5.14 |
| 03:01 ET | 194 | 5.1435 |
| 03:08 ET | 779 | 5.1615 |
| 03:14 ET | 100 | 5.225 |
| 03:19 ET | 100 | 5.22 |
| 03:24 ET | 300 | 5.1923 |
| 03:32 ET | 100 | 5.22 |
| 03:42 ET | 100 | 5.24 |
| 03:46 ET | 100 | 5.26 |
| 03:48 ET | 100 | 5.26 |
| 03:51 ET | 100 | 5.26 |
| 03:55 ET | 100 | 5.3 |
| 03:57 ET | 1700 | 5.22 |
| 04:00 ET | 3909 | 5.27 |
Oct 23, 2024
Oct 22, 2024
TuHURA Biosciences (NASDAQ:HURA) to Present at the Virtual Investor "New to the Street" Event, from 9:05AM ET on Tuesday Oct 22, 2024 by Dow Jones
9:05AM ET on Tuesday Oct 22, 2024 by Dow Jones
Oct 16, 2024
*DJ Correct: Kintara Expected to Begin Trading on Post-Reverse Stk Split Basis on Nasdaq on Oct 18 Under New Name TuHURA Biosciences, Inc. >KTRA, from 1:11PM ET on Wednesday Oct 16, 2024 by Dow Jones
1:11PM ET on Wednesday Oct 16, 2024 by Dow JonesKintara Therapeutics Announces Correction to Prior Announcement Regarding 1-for-35 Reverse Stock Split in Connection with the Proposed Merger with TuHURA Biosciences to Close on October 18, 2024, from 12:54PM ET on Wednesday Oct 16, 2024 by Dow Jones
12:54PM ET on Wednesday Oct 16, 2024 by Dow Jones*DJ Kintara: Expected to Begin Trading on Post-Reverse Stk Split Basis on Nasdaq on Oct 18 Under New Name TuHURA Biosciences, Inc., Symbol 'HURA' Following Anticipated Closing of Merger >KTRA, from 12:01PM ET on Wednesday Oct 16, 2024 by Dow Jones
12:01PM ET on Wednesday Oct 16, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
TuHURA Biosciences Inc | 221.5M | -0.1x | --- |
Solid Biosciences Inc | 222.7M | -1.7x | --- |
Corbus Pharmaceuticals Holdings Inc | 223.1M | -3.2x | --- |
Cabaletta Bio Inc | 223.7M | -2.4x | --- |
XBiotech Inc | 224.2M | -6.4x | --- |
Kyverna Therapeutics Inc | 227.0M | 0.0x | --- |
Company Information
TuHURA Biosciences, Inc. is a Phase III registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The Company’s lead personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase III registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first line treatment for advanced Merkel cell carcinoma. In addition, the Company is leveraging its Delta receptor technology to develop novel bi-functional antibody drug conjugates (ADCs), targeting myeloid derived suppressor cells to inhibit their immune suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies. Its IFx platform technology utilizes a proprietary plasmid DNA (pDNA) or messenger RNA (mRNA).
Contact Information
- Headquarters
- 10500 University Center Dr., Suite 110TAMPA, FL, United States 33612
- Phone
- 813-875-6600
- Fax
- 604-202-1384
Executives
- Chairman of the Board
- Robert Hoffman
- Chief Executive Officer, Director
- James Bianco
- Chief Financial Officer
- Daniel Dearborn
- Senior Vice President, Business Development
- John Liatos
- Chief Scientific Officer
- Dennis Yamashita
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $221.5M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 42.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.78 |
EPS | $-75.24 |
Book Value | $2.38 |
P/E Ratio | -0.1x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
